retatrutide clinical trial thailand Thailand: Availability & Safe Use patientsafety #publichealth #healthcareleadership #medicalethics #drugsafety

US retailers that move early to tailor product ranges and merchandise their shelves targeting GLP-1 users may be better positioned to protect share as eating behaviors change. GlobalData projects that the GLP-1 pill market will grow from $3.2 billion in 2025 to $34.3 billion in 2031, with an annual CAGR of 48.4% over the six-year period

Compounded GLP-1 and dual GIP/GLP-1 receptor agonists: a Statement from the American Diabetes Association

Recently, to ensure the safety of GLP-1 RA on sarcopenia, a clinical randomized multicenter trial of bimagrumab, an antibody blockade of activin type II receptor inhibitor, alone or in addition to subcutaneous semaglutide is now ongoing (NCT05616013) [113]

In brief Shifting health priorities are influencing alcohol choices across demographics, occasions and household dynamics